Skip to main content
. 2021 Aug 10;9(8):e002891. doi: 10.1136/jitc-2021-002891

Figure 3.

Figure 3

Correlation between oncogene drivers and tumor mutational burden, progression-free survival and clinical outcome on immune checkpoint blockade therapy. Dot sizes are proportional to sample size; red: high PD-L1 expression; gray: intermediate PD-L1 expression; blue: low PD-L1 expression.